Navigation Links
OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
Date:7/18/2011

or these complex cases."

The study included 26 patients who underwent PCI and 20 patients then received non-cardiac surgical intervention within 60 days of the PCI. The primary outcome of the study was the occurrence of cardiac death, myocardial infarction (MI), ST and MACE. According to the American Heart Association /American College of Cardiology (AHA/ACC) guidelines, non-cardiac surgery should be delayed by four to six weeks following PCI with a bare metal stent (BMS) and one year following PCI with a drug eluting stent (DES).

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-hea
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
2. OrbusNeichs Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
3. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
4. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
5. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
6. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
7. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
8. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
9. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
10. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
11. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WOONSOCKET, R.I. , Sept. 19, 2014 ... (NYSE: CVS ), will speak before the National ...  Merlo will discuss the company,s recent move to stop selling ... to shape the future of health. "Dramatic changes ... consumers, health care providers and government," Merlo has said. "CVS ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... Dec. 1, 2011 Arbor Pharmaceuticals announced today that it ... the U.S. Food and Drug Administration (FDA).  The recently ... the FDA which provides seven years of market exclusivity. ... status for this product primarily due to the safety ...
... Novelos Therapeutics, Inc. (OTCBB: NVLT) , a pharmaceutical company ... announced the pricing of an underwritten public offering of 9,840,000 ...  Each unit consists of one share of common stock and ... warrants will have an exercise price of $0.60 per share ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2Novelos Therapeutics Prices $5.9 Million Public Offering 2
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... September 21, 2014 More than ... been added over the past month to a ... serious cardiovascular injuries caused by the dialysis concentrate, ... updated on September 15th shows 2,089 cases filed ... District Court, District of Massachusetts. These claims were ...
(Date:9/21/2014)... Recently, BambooIndustry.com, an experienced producer of natural bamboo items, ... ( http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are very ... at discounted prices now, from 10 to 30 percent ... are available in many specifications; they are promised ... is finely manufactured by qualified workers. They are specially ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... in four teenagers who had meningitis during infancy will not ... in Archives of Disease in Childhood. ,The findings ... year olds across England and Wales, 461 of whom had ... ,The children were all taking part in a long ...
... Scientists of University College London have conducted a study ... is indeed responsible// for dyscalculia or in ... hope the findings will aid in the diagnosis and ... ,Dyscalculia is just as prevalent in the population as ...
... the Victorian disease tuberculosis is on the march. Figures released by ... percent in number of TB cases over the last year. ... on the 24th of March, are provisional and relate ... account for the highest proportion of cases (42 percent) but the ...
... Steriani Elavsky, women passing through their menopause are reported to ... improvements in heart and respiratory fitness are said to have ... ,This research was carried out on 164 inactive menopausal ... basis. One group was assigned to perform Yoga while the ...
... junior doctors' has been reduced in order to increase their ... medics found that cutting down working hours alone is not ... of rotas was essential. ,The Occupational and Environmental ... Auckland universities in New Zealand. ,In the UK, ...
... that the odds of firefighters dying from coronary heart disease ... 100 times higher than during non-emergency duties such as rescuing ... Harvard Medical School and colleagues say episodic physical and psychological ... of physical fitness appeared responsible for it. ,Even though ...
Cached Medicine News:Health News:Reason Behind Dyscalculia Revealed 2Health News:TB Cases on the Rise 2Health News:Rest for Doctors to Ensure Patients’ Safet 2Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2
... The D.O.R.C. Associate® is an ... a Peristaltic and Venturi pump, allowing ... mode for Phaco or Vitrectomy procedures.,The ... is a microprocessor-controlled vacuum system that ...
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media.(Sterile, 10 ml.)...
Medicine Products: